| 1 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7519).
|
| 2 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 3 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 4 |
Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
|
| 5 |
ClinicalTrials.gov (NCT02324998) Study of Olaparib ( Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
|
| 6 |
ClinicalTrials.gov (NCT03057145) Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
|
| 7 |
ClinicalTrials.gov (NCT04197713) Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
|
| 8 |
ClinicalTrials.gov (NCT00707707) Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
|
| 9 |
ClinicalTrials.gov (NCT00516438) Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
|
| 10 |
ClinicalTrials.gov (NCT02681237) A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
|
| 11 |
ClinicalTrials.gov (NCT00516724) Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
|
| 12 |
ClinicalTrials.gov (NCT01063517) Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
|
| 13 |
ClinicalTrials.gov (NCT03553108) A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
|
| 14 |
ClinicalTrials.gov (NCT01858168) Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
|
| 15 |
ClinicalTrials.gov (NCT04633239) Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
|
| 16 |
ClinicalTrials.gov (NCT03742245) Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
|
| 17 |
ClinicalTrials.gov (NCT02398058) Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
|
| 18 |
ClinicalTrials.gov (NCT02093351) To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
|
| 19 |
ClinicalTrials.gov (NCT05900895) Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
|
| 20 |
ClinicalTrials.gov (NCT04614909) Study of Pamiparib in Newly Diagnosed and rGBM
|
| 21 |
ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
|
| 22 |
ClinicalTrials.gov (NCT03924245) Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
|
| 23 |
ClinicalTrials.gov (NCT02208375) mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
|
| 24 |
ClinicalTrials.gov (NCT03162627) Selumetinib and Olaparib in Solid Tumors
|
| 25 |
ClinicalTrials.gov (NCT05358639) Combination of Olaparib and Navitoclax in Women With HGSC and TNBC
|
| 26 |
ClinicalTrials.gov (NCT03641755) Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
|
| 27 |
ClinicalTrials.gov (NCT04566952) Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
| 28 |
ClinicalTrials.gov (NCT05536128) Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
|
| 29 |
ClinicalTrials.gov (NCT03579316) Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
| 30 |
ClinicalTrials.gov (NCT03127215) Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
|
| 31 |
ClinicalTrials.gov (NCT02340611) A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
|
| 32 |
ClinicalTrials.gov (NCT04038502) Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
|
| 33 |
ClinicalTrials.gov (NCT03740165) Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
|
| 34 |
ClinicalTrials.gov (NCT05171816) Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
|
| 35 |
ClinicalTrials.gov (NCT04729387) Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
|
| 36 |
ClinicalTrials.gov (NCT05078671) Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
|
|
|
|
|
|
|
